Why Rivian Automotive (RIVN) Is Down 13.5% After Robotaxi Deal And R2 Capacity Expansion News

Rivian Automotive

Rivian Automotive

RIVN

0.00

  • In recent days, Rivian Automotive disclosed a major robotaxi agreement with Uber for up to 50,000 autonomous R2 SUVs, expanded its Georgia plant’s planned capacity to 300,000 vehicles annually backed by a revised US$4.50 billion DOE loan, and reported first-quarter 2026 revenue of US$1.38 billion with a net loss of US$416 million.
  • These moves, alongside fresh equity funding rounds with Volkswagen and SMB Holding and an omnibus shelf filing, highlight Rivian’s shift toward capital-intensive growth in autonomous mobility and scaled R2 production while still operating with ongoing losses.
  • We’ll now examine how Rivian’s Uber robotaxi deal and Georgia capacity expansion reshape its existing investment narrative around R2 and autonomy.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Rivian Automotive Investment Narrative Recap

To own Rivian today, you need to believe it can turn its R2 platform, autonomy stack and growing partnerships into a profitable, scaled EV business despite ongoing losses. The Uber robotaxi deal and Georgia capacity lift reinforce the R2 and autonomy story, but they also sharpen the short term catalyst and risk: Rivian’s ability to fund and execute heavy spending without stretching its balance sheet or needing increasingly dilutive capital raises.

Among the recent updates, Rivian’s Q1 2026 results are particularly relevant. Revenue rose to US$1,381 million while net loss narrowed to US$416 million, showing some operational progress even as the company remains firmly in the red. Against a backdrop of equity raises, a US$4,500 million DOE loan for Georgia, and the Uber robotaxi order, these numbers frame the key question of whether Rivian can move toward better unit economics fast enough.

Yet beneath the promise of robotaxis and new plants, investors should also be aware of the ongoing high cash burn and potential dilution risks that...

Rivian Automotive's narrative projects $15.7 billion revenue and $788.9 million earnings by 2028. This requires 44.9% yearly revenue growth and an earnings increase of about $4.3 billion from -$3.5 billion today.

Uncover how Rivian Automotive's forecasts yield a $16.96 fair value, a 20% upside to its current price.

Exploring Other Perspectives

RIVN 1-Year Stock Price Chart
RIVN 1-Year Stock Price Chart

Some of the lowest ranked analysts were already assuming about 29 percent annual revenue growth to roughly US$11.6 billion by 2029, yet still saw persistent losses and heavy dilution risks as central. Their view is more pessimistic than the baseline narrative, and after Rivian’s Uber robotaxi deal and Georgia expansion, it is worth asking how those forecasts and your own expectations might shift.

Explore 5 other fair value estimates on Rivian Automotive - why the stock might be worth just $16.96!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

  • A great starting point for your Rivian Automotive research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
  • Our free Rivian Automotive research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Rivian Automotive's overall financial health at a glance.

Looking For Alternative Opportunities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

  • Capitalize on the AI infrastructure supercycle with our selection of the 39 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
  • AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
  • We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.